| Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective M Shebley, P Sandhu, A Emami Riedmaier, M Jamei, R Narayanan, ... Clinical Pharmacology & Therapeutics 104 (1), 88-110, 2018 | 308 | 2018 |
| The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models ST Durant, L Zheng, Y Wang, K Chen, L Zhang, T Zhang, Z Yang, ... Science advances 4 (6), eaat1719, 2018 | 246 | 2018 |
| The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans YM Loo, PM McTamney, RH Arends, ME Abram, AA Aksyuk, S Diallo, ... Science translational medicine 14 (635), eabl8124, 2022 | 187 | 2022 |
| Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future opportunities, and … KS Taskar, V Pilla Reddy, H Burt, MM Posada, M Varma, M Zheng, ... Clinical Pharmacology & Therapeutics 107 (5), 1082-1115, 2020 | 102 | 2020 |
| Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations V Pilla Reddy, K Bui, G Scarfe, D Zhou, M Learoyd Clinical Pharmacology & Therapeutics 105 (1), 229-241, 2019 | 58 | 2019 |
| Development, verification, and prediction of osimertinib drug–drug interactions using PBPK modeling approach to inform drug label V Pilla Reddy, M Walker, P Sharma, P Ballard, K Vishwanathan CPT: Pharmacometrics & Systems Pharmacology 7 (5), 321-330, 2018 | 53 | 2018 |
| Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders VP Reddy, M Kozielska, M Johnson, A Vermeulen, R de Greef, J Liu, ... Clinical pharmacokinetics 50, 429-450, 2011 | 52 | 2011 |
| Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility VP Reddy, M Kozielska, AA Suleiman, M Johnson, A Vermeulen, J Liu, ... Schizophrenia research 146 (1-3), 144-152, 2013 | 48* | 2013 |
| Harnessing meta‐analysis to refine an oncology patient population for physiology‐based pharmacokinetic modeling of drugs E Schwenger, VP Reddy, G Moorthy, P Sharma, H Tomkinson, E Masson, ... Clinical Pharmacology & Therapeutics 103 (2), 271-280, 2018 | 47 | 2018 |
| ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156 B Koneru, A Farooqi, TH Nguyen, WH Chen, A Hindle, C Eslinger, ... Science translational medicine 13 (607), eabd5750, 2021 | 43 | 2021 |
| Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study A Jucaite, P Stenkrona, Z Cselényi, S De Vita, N Buil-Bruna, K Varnäs, ... Neuro-oncology 23 (4), 687-696, 2021 | 43 | 2021 |
| Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats M Kozielska, M Johnson, V Pilla Reddy, A Vermeulen, C Li, S Grimwood, ... Pharmaceutical research 29, 1932-1948, 2012 | 41 | 2012 |
| Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response T Petreus, E Cadogan, G Hughes, A Smith, V Pilla Reddy, A Lau, ... Communications Biology 4 (1), 1001, 2021 | 35 | 2021 |
| Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials VP Reddy, M Kozielska, M Johnson, AA Suleiman, A Vermeulen, J Liu, ... Clinical pharmacokinetics 51, 261-275, 2012 | 34 | 2012 |
| Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics R Jayaraman, VP Reddy, MK Pasha, H Wang, K Sangthongpitag, P Yeo, ... Drug metabolism and disposition 39 (12), 2219-2232, 2011 | 29 | 2011 |
| Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D2 Receptor Occupancy of Olanzapine in Rats M Johnson, M Kozielska, V Pilla Reddy, A Vermeulen, C Li, S Grimwood, ... Pharmaceutical research 28, 2490-2504, 2011 | 29 | 2011 |
| Pharmacokinetics under the COVID‐19 storm V Pilla Reddy, E El‐Khateeb, H Jo, N Giovino, E Lythgoe, S Sharma, ... British journal of clinical pharmacology 89 (1), 158-186, 2023 | 28 | 2023 |
| An investigation into the prediction of in vivo clearance for a range of flavin-containing monooxygenase substrates BC Jones, A Srivastava, N Colclough, J Wilson, VP Reddy, ... Drug metabolism and disposition 45 (10), 1060-1067, 2017 | 26 | 2017 |
| Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors E Banks, M Grondine, D Bhavsar, E Barry, JG Kettle, VP Reddy, C Brown, ... Science Translational Medicine 12 (541), eaaz2481, 2020 | 25 | 2020 |
| Pharmacokinetic–pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements V Pilla Reddy, KJ Petersson, AA Suleiman, A Vermeulen, JH Proost, ... CPT: Pharmacometrics & Systems Pharmacology 1 (9), 1-9, 2012 | 25 | 2012 |
meindert danhofLeiden University在 casema.nl 的电子邮件经过验证
